JP2008507532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008507532A5 JP2008507532A5 JP2007522685A JP2007522685A JP2008507532A5 JP 2008507532 A5 JP2008507532 A5 JP 2008507532A5 JP 2007522685 A JP2007522685 A JP 2007522685A JP 2007522685 A JP2007522685 A JP 2007522685A JP 2008507532 A5 JP2008507532 A5 JP 2008507532A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- phenyl
- ethylamino
- hydroxyethyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 12
- -1 hydroxy, amino Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 229910052723 transition metal Inorganic materials 0.000 claims 2
- 150000003624 transition metals Chemical class 0.000 claims 2
- TUBIBLGODRGOHP-LJAQVGFWSA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[2-[4-(3-phenylphenoxy)phenyl]ethylamino]ethyl]phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OC=3C=C(C=CC=3)C=3C=CC=CC=3)=CC=2)=C1 TUBIBLGODRGOHP-LJAQVGFWSA-N 0.000 claims 1
- DFYRTAAGPOJRST-MHZLTWQESA-N 2-(hydroxymethyl)-4-[(1r)-1-hydroxy-2-[2-[4-(4-morpholin-4-ylphenoxy)phenyl]ethylamino]ethyl]phenol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCC=2C=CC(OC=3C=CC(=CC=3)N3CCOCC3)=CC=2)=C1 DFYRTAAGPOJRST-MHZLTWQESA-N 0.000 claims 1
- LOTCCABMGTVQJS-PMERELPUSA-N 3-[3-[4-[2-[[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1h-quinolin-5-yl)ethyl]amino]ethyl]phenoxy]phenyl]benzonitrile Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCC(C=C1)=CC=C1OC(C=1)=CC=CC=1C1=CC=CC(C#N)=C1 LOTCCABMGTVQJS-PMERELPUSA-N 0.000 claims 1
- QDZLKIKITHQUSC-UHFFFAOYSA-N 3-[5-[4-[2-[[2-hydroxy-2-(8-hydroxy-2-oxo-1h-quinolin-5-yl)ethyl]amino]ethyl]phenoxy]-2-methoxyphenyl]benzonitrile Chemical compound COC1=CC=C(OC=2C=CC(CCNCC(O)C=3C=4C=CC(=O)NC=4C(O)=CC=3)=CC=2)C=C1C1=CC=CC(C#N)=C1 QDZLKIKITHQUSC-UHFFFAOYSA-N 0.000 claims 1
- OPZBYTUCEDHACG-UHFFFAOYSA-N 3-[5-[4-[2-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]ethyl]phenoxy]-2-methoxyphenyl]benzonitrile Chemical compound C1=C(C=2C=C(C=CC=2)C#N)C(OC)=CC=C1OC(C=C1)=CC=C1CCNCC(O)C1=CC=C(O)C(CO)=C1 OPZBYTUCEDHACG-UHFFFAOYSA-N 0.000 claims 1
- WKNSKEUOAINWIB-PMERELPUSA-N 4-[(1r)-2-[2-[4-[3-(2-amino-3-ethylphenyl)-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound CCC1=CC=CC(C=2C(=CC=C(OC=3C=CC(CCNC[C@H](O)C=4C=C(CO)C(O)=CC=4)=CC=3)C=2)OC)=C1N WKNSKEUOAINWIB-PMERELPUSA-N 0.000 claims 1
- BIJACFOADCGQPS-UHFFFAOYSA-N 4-[2-[2-[4-[3-(3-chlorophenyl)-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(C=2C=C(Cl)C=CC=2)C(OC)=CC=C1OC(C=C1)=CC=C1CCNCC(O)C1=CC=C(O)C(CO)=C1 BIJACFOADCGQPS-UHFFFAOYSA-N 0.000 claims 1
- FEUHUAULTZZUDS-UHFFFAOYSA-N 4-[2-[2-[4-[3-[3-(aminomethyl)phenyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(C=2C=C(CN)C=CC=2)C(OC)=CC=C1OC(C=C1)=CC=C1CCNCC(O)C1=CC=C(O)C(CO)=C1 FEUHUAULTZZUDS-UHFFFAOYSA-N 0.000 claims 1
- AOQXKTOXEWJGKA-UHFFFAOYSA-N 4-[2-[2-[4-[3-[4-(aminomethyl)phenyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound C1=C(C=2C=CC(CN)=CC=2)C(OC)=CC=C1OC(C=C1)=CC=C1CCNCC(O)C1=CC=C(O)C(CO)=C1 AOQXKTOXEWJGKA-UHFFFAOYSA-N 0.000 claims 1
- JDBAEVYCCGMFJB-SANMLTNESA-N 5-[(1r)-2-[2-[4-[3-(3-aminopropyl)-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=C(CCCN)C(OC)=CC=C1OC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 JDBAEVYCCGMFJB-SANMLTNESA-N 0.000 claims 1
- AAWRYASVGTWNRA-LJAQVGFWSA-N 5-[(1r)-2-[2-[4-[3-(4-chlorophenyl)phenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCC(C=C1)=CC=C1OC(C=1)=CC=CC=1C1=CC=C(Cl)C=C1 AAWRYASVGTWNRA-LJAQVGFWSA-N 0.000 claims 1
- YZWQATVPGZTCBD-MHZLTWQESA-N 5-[(1r)-2-[2-[4-[3-[2-(dimethylamino)ethyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=C(CCN(C)C)C(OC)=CC=C1OC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 YZWQATVPGZTCBD-MHZLTWQESA-N 0.000 claims 1
- XJFXXNRPCNSPIJ-HKBQPEDESA-N 5-[(1r)-2-[2-[4-[3-[3-(2-aminoethyl)phenyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound COC1=CC=C(OC=2C=CC(CCNC[C@H](O)C=3C=4C=CC(=O)NC=4C(O)=CC=3)=CC=2)C=C1C1=CC=CC(CCN)=C1 XJFXXNRPCNSPIJ-HKBQPEDESA-N 0.000 claims 1
- KLKXMOLYQIGTCM-SANMLTNESA-N 5-[(1r)-2-[2-[4-[4-(2-amino-2-methylpropoxy)phenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=CC(OCC(C)(N)C)=CC=C1OC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 KLKXMOLYQIGTCM-SANMLTNESA-N 0.000 claims 1
- AHLFSKLVFVYVKD-DEOSSOPVSA-N 5-[(1r)-2-[2-[4-[4-(2-aminoethoxy)-3-(trifluoromethyl)phenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=C(C(F)(F)F)C(OCCN)=CC=C1OC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 AHLFSKLVFVYVKD-DEOSSOPVSA-N 0.000 claims 1
- ZTNDVILTNKGXJI-SANMLTNESA-N 5-[(1r)-2-[2-[4-[4-(3-aminopropoxy)phenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=CC(OCCCN)=CC=C1OC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 ZTNDVILTNKGXJI-SANMLTNESA-N 0.000 claims 1
- BAYIKWRKACUIDC-MHZLTWQESA-N 5-[(1r)-2-[2-[4-[4-[2-(2-aminoethoxy)ethoxy]phenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound C1=CC(OCCOCCN)=CC=C1OC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 BAYIKWRKACUIDC-MHZLTWQESA-N 0.000 claims 1
- HASPUVUEEXNVQR-UHFFFAOYSA-N 5-[2-[2-[4-[3-(3-chlorophenyl)-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound COC1=CC=C(OC=2C=CC(CCNCC(O)C=3C=4C=CC(=O)NC=4C(O)=CC=3)=CC=2)C=C1C1=CC=CC(Cl)=C1 HASPUVUEEXNVQR-UHFFFAOYSA-N 0.000 claims 1
- QJHFTPQALJUGNJ-UHFFFAOYSA-N 5-[2-[2-[4-[3-[3-(aminomethyl)phenyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound COC1=CC=C(OC=2C=CC(CCNCC(O)C=3C=4C=CC(=O)NC=4C(O)=CC=3)=CC=2)C=C1C1=CC=CC(CN)=C1 QJHFTPQALJUGNJ-UHFFFAOYSA-N 0.000 claims 1
- BTPGXMRGUSJMIG-UHFFFAOYSA-N 5-[2-[2-[4-[3-[4-(aminomethyl)phenyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound COC1=CC=C(OC=2C=CC(CCNCC(O)C=3C=4C=CC(=O)NC=4C(O)=CC=3)=CC=2)C=C1C1=CC=C(CN)C=C1 BTPGXMRGUSJMIG-UHFFFAOYSA-N 0.000 claims 1
- QSYYCQBSKYPHSB-LJAQVGFWSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-(3-phenylphenoxy)phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCC(C=C1)=CC=C1OC(C=1)=CC=CC=1C1=CC=CC=C1 QSYYCQBSKYPHSB-LJAQVGFWSA-N 0.000 claims 1
- GBGVPLDZRAUBBA-LJAQVGFWSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-(4-methoxy-3-phenylphenoxy)phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound COC1=CC=C(OC=2C=CC(CCNC[C@H](O)C=3C=4C=CC(=O)NC=4C(O)=CC=3)=CC=2)C=C1C1=CC=CC=C1 GBGVPLDZRAUBBA-LJAQVGFWSA-N 0.000 claims 1
- QTVLQXVLVMAMDH-MHZLTWQESA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-(4-morpholin-4-ylphenoxy)phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCC(C=C1)=CC=C1OC(C=C1)=CC=C1N1CCOCC1 QTVLQXVLVMAMDH-MHZLTWQESA-N 0.000 claims 1
- CUNUUUZDIGCWDT-PMERELPUSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[3-(4-methoxyphenyl)phenoxy]phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound C1=CC(OC)=CC=C1C1=CC=CC(OC=2C=CC(CCNC[C@H](O)C=3C=4C=CC(=O)NC=4C(O)=CC=3)=CC=2)=C1 CUNUUUZDIGCWDT-PMERELPUSA-N 0.000 claims 1
- GLRBGNJHTNVYML-LJAQVGFWSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[4-(2-morpholin-4-ylethoxy)phenoxy]phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCC(C=C1)=CC=C1OC(C=C1)=CC=C1OCCN1CCOCC1 GLRBGNJHTNVYML-LJAQVGFWSA-N 0.000 claims 1
- ZMHUSGJOZCHZBM-LJAQVGFWSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[4-(2-piperazin-1-ylethoxy)phenoxy]phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCC(C=C1)=CC=C1OC(C=C1)=CC=C1OCCN1CCNCC1 ZMHUSGJOZCHZBM-LJAQVGFWSA-N 0.000 claims 1
- CIJIYHHKRIIRRI-UMSFTDKQSA-N 8-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[4-methoxy-3-[3-(morpholin-4-ylmethyl)phenyl]phenoxy]phenyl]ethylamino]ethyl]-1h-quinolin-2-one Chemical compound COC1=CC=C(OC=2C=CC(CCNC[C@H](O)C=3C=4C=CC(=O)NC=4C(O)=CC=3)=CC=2)C=C1C(C=1)=CC=CC=1CN1CCOCC1 CIJIYHHKRIIRRI-UMSFTDKQSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- MCANLJLDYKNECQ-LJAQVGFWSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-(3-phenylphenoxy)phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C([C@H](O)C=1C=C(NC=O)C(O)=CC=1)NCCC(C=C1)=CC=C1OC(C=1)=CC=CC=1C1=CC=CC=C1 MCANLJLDYKNECQ-LJAQVGFWSA-N 0.000 claims 1
- SIVLLCMFRSBPLH-MHZLTWQESA-N n-[5-[(1r)-2-[2-[4-[3-[2-(dimethylamino)ethyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-hydroxyphenyl]formamide Chemical compound C1=C(CCN(C)C)C(OC)=CC=C1OC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C(NC=O)=C1 SIVLLCMFRSBPLH-MHZLTWQESA-N 0.000 claims 1
- RLNZXSZYXZNWGQ-VWLOTQADSA-N n-[5-[(1r)-2-[2-[4-[4-(2-aminoethoxy)phenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-hydroxyphenyl]formamide Chemical compound C1=CC(OCCN)=CC=C1OC(C=C1)=CC=C1CCNC[C@H](O)C1=CC=C(O)C(NC=O)=C1 RLNZXSZYXZNWGQ-VWLOTQADSA-N 0.000 claims 1
- ASMRTVSGUNPMHW-UHFFFAOYSA-N n-[5-[2-[2-[4-[3-(3-chlorophenyl)-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-hydroxyphenyl]formamide Chemical compound C1=C(C=2C=C(Cl)C=CC=2)C(OC)=CC=C1OC(C=C1)=CC=C1CCNCC(O)C1=CC=C(O)C(NC=O)=C1 ASMRTVSGUNPMHW-UHFFFAOYSA-N 0.000 claims 1
- RFRFJILDRYFSSN-UHFFFAOYSA-N n-[5-[2-[2-[4-[3-[3-(aminomethyl)phenyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-hydroxyphenyl]formamide Chemical compound C1=C(C=2C=C(CN)C=CC=2)C(OC)=CC=C1OC(C=C1)=CC=C1CCNCC(O)C1=CC=C(O)C(NC=O)=C1 RFRFJILDRYFSSN-UHFFFAOYSA-N 0.000 claims 1
- WJLANEUKLAWUQB-UHFFFAOYSA-N n-[5-[2-[2-[4-[3-[4-(aminomethyl)phenyl]-4-methoxyphenoxy]phenyl]ethylamino]-1-hydroxyethyl]-2-hydroxyphenyl]formamide Chemical compound C1=C(C=2C=CC(CN)=CC=2)C(OC)=CC=C1OC(C=C1)=CC=C1CCNCC(O)C1=CC=C(O)C(NC=O)=C1 WJLANEUKLAWUQB-UHFFFAOYSA-N 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 0 CC*(c1c(*=*)c(*)cc(C(C(C)*)OC)c1C(C)=*)=C Chemical compound CC*(c1c(*=*)c(*)cc(C(C(C)*)OC)c1C(C)=*)=C 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58972804P | 2004-07-21 | 2004-07-21 | |
| PCT/US2005/025690 WO2006014704A1 (en) | 2004-07-21 | 2005-07-20 | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008507532A JP2008507532A (ja) | 2008-03-13 |
| JP2008507532A5 true JP2008507532A5 (OSRAM) | 2008-08-07 |
Family
ID=35064743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007522685A Withdrawn JP2008507532A (ja) | 2004-07-21 | 2005-07-20 | ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US7317023B2 (OSRAM) |
| EP (1) | EP1778638A1 (OSRAM) |
| JP (1) | JP2008507532A (OSRAM) |
| WO (1) | WO2006014704A1 (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| JP2008507532A (ja) * | 2004-07-21 | 2008-03-13 | セラヴァンス， インコーポレーテッド | ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト |
| EP1786762A2 (en) * | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| AU2006205933A1 (en) * | 2005-01-11 | 2006-07-20 | Glaxo Group Limited | Cinnamate salts of a beta-2 adrenergic agonist |
| ES2265276B1 (es) * | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| ATE552032T1 (de) | 2005-07-14 | 2012-04-15 | Lithera Inc | Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| US8653145B2 (en) * | 2005-09-22 | 2014-02-18 | Eaton Scientific Systems, Ltd. | Method for alleviating climacteric symptoms |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| GB2443287B (en) * | 2006-10-17 | 2009-05-27 | Lipothera Inc | Methods, compositions and formulations for the treatment of thyroid eye disease |
| ES2302447B1 (es) * | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| ES2306595B1 (es) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
| ES2320961B1 (es) | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
| JP2011524896A (ja) | 2008-06-18 | 2011-09-08 | アストラゼネカ・アクチエボラーグ | 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体 |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
| JP5555255B2 (ja) | 2008-12-30 | 2014-07-23 | プルマゲン セラピューティクス（インフラメーション）リミテッド | 呼吸器疾患の治療のためのスルホンアミド化合物 |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| EP2523667A4 (en) * | 2010-01-15 | 2014-04-02 | Lithera Inc | LYOPHILIZED CAKE FORMULATIONS |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| MX2013005873A (es) | 2010-11-24 | 2013-08-07 | Lithera Inc | Formulaciones monoterapeuticas de agonistas beta selectivo, lipofilo y de accion prolongada y procedimientos para el tratamiento cosmetico de adiposidad y abultamiento del contorno. |
| GEP20156285B (en) | 2011-02-25 | 2015-05-11 | Aierem Elelsi | Compounds and compositions as trk inhibitors |
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| EP2647627A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
| WO2016002907A1 (ja) * | 2014-07-02 | 2016-01-07 | 株式会社カネカ | 硬化性組成物およびその硬化物 |
| WO2016027283A2 (en) * | 2014-08-22 | 2016-02-25 | Reddy G Pratap | A process for preparing indacaterol and salts thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2266497B1 (OSRAM) | 1974-04-03 | 1977-11-04 | Roussel Uclaf | |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| CA1262729A (en) * | 1983-10-19 | 1989-11-07 | Leo Alig | Phenoxypropanolamines |
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| US4894219A (en) * | 1988-03-29 | 1990-01-16 | University Of Florida | Beta-agonist carbostyril derivatives, assay method and pharmacological composition |
| ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| ATE266639T1 (de) * | 1997-10-17 | 2004-05-15 | Yamanouchi Pharma Co Ltd | Amidderivate oder deren salze |
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6436914B1 (en) * | 1998-06-30 | 2002-08-20 | Bristol-Myers Squibb Company | 2-hydroxy-3—(4-hydroxy-3-sulfonamidophenyl)—propylamines useful as beta 3 adrenergic agonists |
| US20020143034A1 (en) * | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| AU6050000A (en) | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
| MXPA02004653A (es) | 1999-11-15 | 2002-09-02 | Lilly Co Eli | Ariloxipropanolaminas para mejorar la produccion de ganado. |
| AU1572701A (en) | 1999-11-15 | 2001-05-30 | Eli Lilly And Company | Treating wasting syndromes with aryloxy propanolamines |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| EP1305300A1 (de) * | 2000-04-27 | 2003-05-02 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| CA2415331A1 (en) | 2000-07-13 | 2002-01-24 | Eli Lilly And Company | Beta3 adrenergic agonists |
| DE60120748T2 (de) | 2000-11-10 | 2007-05-16 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindolderivate als beta-3-agonisten |
| ES2288543T3 (es) * | 2001-03-08 | 2008-01-16 | Glaxo Group Limited | Agonistas de beta-adrenorreceptores. |
| DE10293175D2 (de) * | 2001-07-19 | 2004-07-01 | Luk Lamellen & Kupplungsbau | System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges unter Berücksichtigung eines Fluidverlustes |
| CA2458534C (en) | 2001-09-14 | 2011-11-01 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| US6653323B2 (en) * | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| RU2319698C2 (ru) | 2002-06-27 | 2008-03-20 | Астеллас Фарма Инк. | АЛЬФА-ФЕНИЛ ИЛИ ПИРИДИЛ-ЭТАНОЛАМИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АГОНИСТОВ β3 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| JP2008501705A (ja) * | 2004-06-03 | 2008-01-24 | セラヴァンス， インコーポレーテッド | ジアミンβ２アドレナリン作用性レセプターアゴニスト |
| JP2008507532A (ja) * | 2004-07-21 | 2008-03-13 | セラヴァンス， インコーポレーテッド | ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト |
-
2005
- 2005-07-20 JP JP2007522685A patent/JP2008507532A/ja not_active Withdrawn
- 2005-07-20 EP EP05779346A patent/EP1778638A1/en not_active Withdrawn
- 2005-07-20 WO PCT/US2005/025690 patent/WO2006014704A1/en not_active Ceased
- 2005-07-20 US US11/185,295 patent/US7317023B2/en not_active Expired - Lifetime
-
2007
- 2007-11-19 US US11/985,987 patent/US7662815B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008507532A5 (OSRAM) | ||
| JP2005527618A5 (OSRAM) | ||
| RU2009118825A (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1ГИДРОКСИЭТИЛ)ФЕНОЛА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JP2007518738A5 (OSRAM) | ||
| JP2008512470A5 (OSRAM) | ||
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| JP2007505931A5 (OSRAM) | ||
| RU2006129312A (ru) | Производные ариланилина в качестве агонистов 2 адренергического рецептора | |
| JP2002516314A5 (OSRAM) | ||
| JP2011504485A5 (OSRAM) | ||
| CN101432268A (zh) | 作为β2肾上腺素受体激动剂的4-(2-氨基-1-羟乙基)酚衍生物 | |
| JP2007519692A5 (OSRAM) | ||
| JP2004520292A5 (OSRAM) | ||
| JP2009523165A5 (OSRAM) | ||
| CA2375810A1 (en) | Beta2-adrenoceptor agonists | |
| JP2013517283A5 (OSRAM) | ||
| JP2007509852A5 (OSRAM) | ||
| CN105492027A (zh) | 具有毒蕈碱受体拮抗体和β2肾上腺素能受体激动剂两种活性的2-氨基-1-羟乙基-8-羟基喹啉-2(1H)-酮衍生物的盐 | |
| CA2563302A1 (en) | Combinations of glycopyrrolate and beta2 adrenoceptor agonists | |
| JP2008543860A5 (OSRAM) | ||
| JP2007509103A5 (OSRAM) | ||
| CA2628844A1 (en) | Pyrazole derivatives and their medical use | |
| JP2007519695A5 (OSRAM) | ||
| JP2007506749A5 (OSRAM) | ||
| CA2464367A1 (en) | Bicyclic compounds |